Literature DB >> 25364760

PrP(C) from stem cells to cancer.

Séverine Martin-Lannerée1, Théo Z Hirsch1, Julia Hernandez-Rapp2, Sophie Halliez3, Jean-Luc Vilotte4, Jean-Marie Launay5, Sophie Mouillet-Richard1.   

Abstract

The cellular prion protein PrP(C) was initially discovered as the normal counterpart of the pathological scrapie prion protein PrP(Sc), the main component of the infectious agent of Transmissible Spongiform Encephalopathies. While clues as to the physiological function of this ubiquitous protein were greatly anticipated from the development of knockout animals, PrP-null mice turned out to be viable and to develop without major phenotypic abnormalities. Notwithstanding, the discovery that hematopoietic stem cells from PrP-null mice have impaired long-term repopulating potential has set the stage for investigating into the role of PrP(C) in stem cell biology. A wealth of data have now exemplified that PrP(C) is expressed in distinct types of stem cells and regulates their self-renewal as well as their differentiation potential. A role for PrP(C) in the fate restriction of embryonic stem cells has further been proposed. Paralleling these observations, an overexpression of PrP(C) has been documented in various types of tumors. In line with the contribution of PrP(C) to stemness and to the proliferation of cancer cells, PrP(C) was recently found to be enriched in subpopulations of tumor-initiating cells. In the present review, we summarize the current knowledge of the role played by PrP(C) in stem cell biology and discuss how the subversion of its function may contribute to cancer progression.

Entities:  

Keywords:  cancer; cell fate specification; cellular prion protein; prion infection; self-renewal; stem cell

Year:  2014        PMID: 25364760      PMCID: PMC4207012          DOI: 10.3389/fcell.2014.00055

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


Introduction

The discovery of the cellular prion protein PrPC dates back to 1985 with the identification that the scrapie prion protein PrPSc, the main component of the infectious agent responsible for Transmissible Spongiform Encephalopathies (TSEs) was encoded by a gene of the host, termed Prnp (Oesch et al., 1985). PrPC has been extensively scrutinized as the endogenous substrate for conversion into its pathogenic PrPSc counterpart (Aguzzi and Calella, 2009), while studies on its physiological function have long been overlooked. At the molecular and cellular levels, it is well established that PrPC is anchored to the outer leaflet of the plasma membrane through a glycosyl-phosphatidylinositol (GPI) moiety (Linden et al., 2008). It may exist under a great diversity of isoforms as a result of heterogeneous glycosylation (Ermonval et al., 2003) and proteolytic cleavage (McDonald et al., 2014). Although it is suspected that the wide repertoire of PrPC species may endow the protein with the capacity to interact with multiple soluble ligands, extracellular matrix components or cell-surface proteins, the specific tissue distribution, and function of each isoform remain elusive (Linden et al., 2008). That research on PrPC function has lagged behind that of TSE pathophysiology may notably be explained by the lack of major abnormalities in PrP-null mice (Steele et al., 2007), whose most obvious phenotype is their resistance to TSE agents (Bueler et al., 1993). Because PrP is ubiquitously expressed and very much conserved in mammals, with Prnp orthologs identified in fish, birds, and reptiles (Premzl and Gamulin, 2007), the apparent normal phenotype of PrP null mice was quite unexpected and proposed to reflect the occurrence of compensatory mechanisms. One major contribution of these mice, however, was the demonstration that PrPC is mandatory for the long-term repopulating activity of hematopoietic stem cells (HSCs) (see below) (Zhang et al., 2006). This seminal report set the stage for investigating into the role exerted by PrPC in stem cell biology. Here, we provide an overview of the recent advances regarding the contribution of PrPC to stem cell biology and their pathophysiological implications.

PrPC expression and role during development

Studies on PrPC have initially focused on the adult central nervous system (CNS), since it is the only target of PrPSc-associated toxicity (Aguzzi and Calella, 2009). Further, PrPC is most abundantly found in neurons (Linden et al., 2008). Notwithstanding, PrPC is highly expressed during embryonic development, as first shown by Manson et al. over two decades ago (Manson et al., 1992). This in situ hybridization analysis revealed widespread expression of Prnp transcripts in the developing central and peripheral nervous system at embryonic days E13.5 and E16.5, as well as in other tissues such as the intestine or the dental lamina (Manson et al., 1992). Prnp mRNA was also detected in extra-embryonic tissues from E6.5, pointing for the first time to a potential role for PrPC in the placenta, which has started to be accurately assessed recently (Alfaidy et al., 2012; Passet et al., 2012). These first data were refined with the detection of Prnp mRNA starting at E8.5–E9 in the differentiating neuroepithelium (Miele et al., 2003). The induction of Prnp expression at this stage in the developing CNS and heart was confirmed in a study using Prnp-LacZ reporter mice (Tremblay et al., 2007). Based on this developmental pattern of expression, transcriptomic analyses were carried out on early Prnp knockout vs. wild-type (WT) embryos and revealed prominent alterations, with a total number of 263 genes differentially expressed at day E7.5 (Khalife et al., 2011). The array of genes with altered expression notably includes a set of growth factors and growth factor receptors, supporting the notion that PrPC plays an important role in the regulation of cascades associated with embryonic development (Khalife et al., 2011). Interestingly, the pattern of pathways affected overlaps with that obtained after early embryonic gene expression profiling of zebrafish PrP2 morphants (Nourizadeh-Lillabadi et al., 2010). The zebrafish model actually allowed bringing to light a vital function for PrPC since morpholino-mediated knockdown of the PrP ortholog PrP1 in this species leads to loss of embryonic cell adhesion and gastrulation arrest (Malaga-Trillo et al., 2009). Of note, the defects observed could be rescued with mouse Prnp mRNA, indicating that this function is evolutionary conserved (Malaga-Trillo et al., 2009). Thus, the overall data gained at the animal scale argue that PrPC fulfills an important function during embryogenesis and that its ablation in mice triggers the implementation of yet-to-be-deciphered compensatory mechanisms.

PrPC regulates the self-renewal of stem/progenitor cells

The link between PrPC and stem cell biology was first uncovered in HSCs. Investigations of PrPC in the hematopoietic system were initially prompted by the observation that PrPSc accumulates in lymphoid organs and by the quest to understand the cellular mechanisms sustaining prion propagation in the periphery (Mabbott and MacPherson, 2006). These studies demonstrated that PrPC is highly expressed at the surface of various hematopoietic cells, including B and T lymphocytes, monocytes, dendritic cells, megakaryocytes and platelets, but not erythrocytes or granulocytes (Linden et al., 2008). In the human bone marrow, PrPC was found to be present in the CD34+ stem / progenitor cell population (Dodelet and Cashman, 1998) and to be preferentially expressed on murine CD43+, B220−, IL-7R− cells, enriched in immature progenitors (Liu et al., 2001). A major advance was the discovery by the team of Lodish that PrPC is very abundant at the surface of mouse bone marrow Lin−Sca+Endoglin+ cells, a population comprising immature HSCs (Zhang et al., 2006). These authors then assessed the ability of bone marrow-derived Lin−Sca+Endoglin+ cells from Prnp knockout mice to reconstitute the hematopoietic system of lethally irradiated mice in serial transplantation assays, and demonstrated that HSCs from Prnp null mice lack long-term repopulating activity (see Table 1) (Zhang et al., 2006). These experiments further allowed substantiating that the Lin−Sca+Endoglin+ cell population endowed with long-term repopulating activity is PrPC positive (Zhang et al., 2006).
Table 1

Summary of effects of PrP.

Cell type/tissuePrPC-null/KD vs. wtReferences
EMBRYO/POSTNATAL
ESIncreased apoptosis in embryoid bodiesMiranda et al., 2011
Human ESInhibition of ectodermal differentiationLee and Baskakov, 2012
Reduced transition from G1 to S phase during spontaneous differentiation
Multipotent neural precursors E13.5 (telencephalon)Delayed neuronal differentiationSteele et al., 2006
Neurospheres isolated from E14 forebrainReduced neurosphere formationSantos et al., 2011
E16.5 oligodendrocyte precursor cells (OPC) in optic nerve explantsIncreased proliferation (BrdU incorporation)Bribian et al., 2012
E16.5 neocortexIncreased NG2+ Olig2+ OPCBribian et al., 2012
P0-P2 cortical OPC primary cultureDelayed differentiationBribian et al., 2012
P5 neurospheres isolated from SVZReduced proliferation (BrdU incorporation) and secondary neurosphere formationProdromidou et al., 2014
ADULT
Dentate gyrusReduced proliferation (BrdU incorporation)Steele et al., 2006
Reduced proliferation of neuroprogenitors and/or neurogenesis (BrdU+ NeuN+)Bribian et al., 2012
NeocortexIncreased NG2+ Olig2+ OPCBribian et al., 2012
SVZReduction of cycling GFAP+ neural stem cellsProdromidou et al., 2014
Decreased Mash+ progenitors and accumulation of proliferating neuroblasts DCX+
HSCLoss of long-term repopulating activity in serial transplantation assaysZhang et al., 2006
Skeletal muscleDelayed regeneration after injury (retarded exit from the cell cycle of myogenic precursor cells)Stella et al., 2010
Human MSCReduced clonogenic potential, proliferation and differentiationMohanty et al., 2012
Summary of effects of PrP. Much like HSCs, neuroepithelial stem cells have the capacity to proliferate through repeated symmetric divisions and generate radial glial cells, which then undergo asymmetric division and give rise to neurons, oligodendrocytes, and astrocytes (Gotz and Huttner, 2005). The proper proceeding of these expansive and neurogenic phases is crucial for the development of the CNS. By comparing neural stem cells isolated from Prnp knockout, WT or PrP overexpressing mice at embryonic day 13.5, Steele et al. documented that PrPC levels directly increase the differentiation rate of multipotent neural precursor cells (Steele et al., 2006). In the same study, PrPC expression levels were further found to correlate with the proliferation rate in the two adult neurogenic regions, the subventricular zone (SVZ) or the dentate gyrus (DG) (Steele et al., 2006). The latter finding was corroborated by two independent studies showing that the formation of neurospheres from fetal (Santos et al., 2011) or postnatal (Prodromidou et al., 2014) brains is less efficient with Prnp knockout than WT mice. The notion that PrPC contributes to the proliferation of stem cells extends beyond hematopoietic and neural stem cells. Indeed, the level of PrPC was found to serve as an effective cell surface marker for self-renewing mammary gland stem cells in mice (Liao et al., 2007). More recently, PrPC was further shown to promote the expansion and engraftment of bone marrow-derived human mesenchymal stem cells (MSCs) (Mohanty et al., 2012). Finally, PrPC was shown to exert either an anti- or a pro-proliferative effect in human embryonic stem (ES) cells, depending on whether they are grown under self-renewing or differentiating conditions, respectively (Lee and Baskakov, 2012).

PrPC influences stem cell fate

The identification of PrPC as a broad cell surface marker for stem / progenitor cells raises the question as to whether the expression of PrPC is a determinant of the stem cell fate. In this respect, we (Mouillet-Richard et al., 1999) and others (Peralta et al., 2011) have provided evidence that PrPC is upregulated following the cell fate restriction of multipotential ES or embryonic carcinoma (EC) cells toward the neuronal lineage. Similarly, PrPC is induced in ES-derived cardiomyogenic progenitors obtained after embryoid body (EB) formation (Hidaka et al., 2010). In line with this, the expression of PrPC was found to be increased during spontaneous differentiation of mouse and human ES cells (Lee and Baskakov, 2010; Miranda et al., 2011) and, reciprocally, induction of PrPC in human ES cells grown under self-renewal conditions was shown to promote their differentiation (Lee and Baskakov, 2012). Intriguingly, exposure of ES cells to recombinant PrP delays their spontaneous differentiation (Lee and Baskakov, 2010). In view of the early expression of PrPC in extra-embryonic tissues, it is tempting to speculate that placenta-derived PrPC may serve as a paracrine signal to maintain the self-renewal of inner mass cells, until their appropriate induction toward either of the three lineages. Beyond lineage specification, the regulation of PrPC expression also accompanies differentiation toward a given fate. Along the hematopoietic lineage, PrPC appears to be downregulated upon differentiation of CD34+ progenitors toward a granulocytic fate, while its expression is retained in B and T lymphocytes as well as monocytes (Dodelet and Cashman, 1998). In addition, PrPC is absent from erythrocytes (Dodelet and Cashman, 1998) and abundant in megakaryocytes and platelets (Starke et al., 2005), suggesting that the expression of PrPC is switched off with the commitment of megakaryocytic-erythrocytic progenitors toward the erythroid fate, or is decreased along erythroid differentiation, in line with (Panigaj et al., 2011). As for neural progenitor cells, the expression of PrPC was reported to be increased along neuronal differentiation, while barely detected in astrocytes or oligodendrocytes (Steele et al., 2006). This high neuronal PrPC expression is in line with the well-documented contribution of PrPC to neuronal differentiation, including neurite outgrowth (Chen et al., 2003; Santuccione et al., 2005; Loubet et al., 2012; Santos et al., 2013) or synapse maturation (Kanaani et al., 2005). The lack of PrPC detection in differentiating oligodendrocytes and astrocytes in the study by Steele et al. (2006) is, however, in contrast with several reports documenting an abundant PrPC expression in these two cell types in late embryos or in the postnatal brain (Moser et al., 1995; Lima et al., 2007; Bribian et al., 2012). Interestingly, both oligodendrocytic (Bribian et al., 2012) and astrocytic (Arantes et al., 2009) differentiation kinetics appear to be delayed in Prnp knockout mice. These observations recall the delay in neuronal differentiation, as initially reported by Steele et al. (2006), as well as the slower regeneration of muscle after injury (Stella et al., 2010) in a PrP null context. Whether PrPC expression affects the balance from one fate to another remains, however, to be investigated. In this regard, it is worth noting that prion infection in adult neural stem cells (NSCs) favors the differentiation toward the glial lineage at the expense of neuronal differentiation (Relaño-Ginés et al., 2013).

Stem cells and prion replication

Whether stem cells are susceptible to prion infection may at first seem a question without relevance, since TSEs are neurodegenerative diseases. However, as rightly underlined in the study by Relaño-Ginés (Relaño-Ginés et al., 2013), exploiting the potential of adult NSCs is currently considered as a promising avenue to mitigate neurodegeneration (Bellenchi et al., 2013). While several studies had reported an efficient replication of PrPSc in neurospheres isolated from fetal brain (Milhavet et al., 2006; Herva et al., 2010), the susceptibility of adult NSC toward prion infection has been evaluated only recently. In line with the results obtained with embryonic-derived cultures, neurospheres isolated from the SVZ or the DG of adult mice were shown to support prion replication (Relaño-Ginés et al., 2013). The same study further documented the presence of dense PrPSc deposits in the DG and the SVZ of prion-infected mice, indicating that prions colonize adult NSCs, the brain's endogenous repair machinery (Relaño-Ginés et al., 2013, 2014). Of note, prion replication of adult NSCs was found to impair neuronal differentiation, both in vitro and in vivo (Relaño-Ginés et al., 2013). Thus, in addition to constituting a reservoir of PrPSc, the replication of prions in adult NSCs may also compromise the regeneration of damaged neurons. Finally, because PrPSc is known to deviate the normal function of PrPC (Westergard et al., 2007; Pradines et al., 2013), these observations suggest that studying the impact of prion infection on the self-renewal and fate of NSCs may improve our understanding of the physiological role exerted by PrPC in these processes.

PrPC-dependent control of stem cell self-renewal and fate: mechanistic insight

Notwithstanding the well-established involvement of PrPC in the self-renewal of diverse types of stem /progenitor cells, the molecular mechanisms at play remain obscure. One possible mode of action of PrPC would be through the interaction with one of its ligands. This view is clearly supported by the demonstration that the binding of PrPC with STI-1 is critical for the formation and proliferation of neurospheres cultured from fetal forebrain (Santos et al., 2011). While several signaling cascades elicited by the interaction of STI-1 with PrPC have been described in a neuronal context (Hirsch et al., 2014), the pathways mobilized to sustain neurosphere self-renewal and proliferation have not been analyzed so far (Santos et al., 2011). On another hand, the presence of PrPC on neurospheres was recently shown to be required for NCAM-induced neuronal differentiation (Prodromidou et al., 2014). These two sets of observations raise the question as to the PrPC isoforms that respectively bind STI-1 and NCAM, since these two molecules instruct distinct responses. Another PrPC partner that may have relevance to stem cell biology is the amyloid precursor protein APP, whose functional interaction with PrP in the zebrafish modulates cell adhesion and CNS development (Kaiser et al., 2012). Whether the APP-PrPC interaction is involved in the regulation of E-cadherin-dependent adhesion in zebrafish embryos deserves further investigation (Malaga-Trillo et al., 2009). Interestingly, our own studies on a neuroectodermal stem cell line also substantiate a disruption of cadherin-mediated cell contacts upon PrPC depletion (Martin-Lannerée et al., unpublished observations). It is of note that cell adhesion processes are now recognized as major determinants of stem cell biology in relation with their local microenvironment (stem cell niche) (Marthiens et al., 2010). By affecting adhesion properties of stem cells, the depletion of PrPC may thus in turn impact on their retention, self-renewal or exit from their niche.

A role for PrPC in cancer stem cells?

The contribution of PrPC to cell proliferation appears to apply to many cell types beyond stem/progenitor cells. These notably include cancer cells, as first demonstrated in gastric tumor cell lines (Liang et al., 2007a). In these cells, PrPC was shown to accelerate the G1 to S phase transition in the cell cycle and to sustain proliferation by inducing the expression of Cyclin D1 through a PI3K/Akt pathway (Liang et al., 2007a). The PrPC-interacting protein(s) involved in this cascade remain(s), however, to be identified. Beyond proliferation, PrPC overexpression in cancer cells was further shown to confer resistance to various cytotoxic agents (Mehrpour and Codogno, 2010) as well as invasive properties (Pan et al., 2006). For instance, PrPC levels were shown to correlate with resistance to TNFα-induced cell death in the MCF-7 breast cancer cell line (Diarra-Mehrpour et al., 2004). Very recently, PrPC was found to interact with the cell surface protein CD44 in adriamycin-resistant breast cancer cells, and to promote their proliferation and migration (Cheng et al., 2013). Interestingly, CD44 has been reported to be enriched at the cell surface of various types of tumor-initiating cells, which bear similarities with embryonic or adult stem cells and are often referred to as cancer stem cells (CSCs) (Medema, 2013). It is also noteworthy that CSCs have been associated with increased resistance to antitumor treatments (Singh and Settleman, 2010). In line with the above-mentioned role of PrPC in the self-renewal of stem cells, Du et al. depicted a population of CD44+PrPC+ cells from primary colorectal tumors endowed with enhanced tumor-initiating and metastatic capacity (Du et al., 2013). At a mechanistic level, PrPC was shown to promote an epithelial to mesenchymal transition (EMT) through the regulation of the Twist transcription factor (Du et al., 2013). These observations are in agreement with the notion that the emergence of CSCs and EMT are intimately connected (Singh and Settleman, 2010). A still unresolved question concerns the molecular mechanisms sustaining the enhanced expression of PrPC in cancer cells. PrPC expression has been shown to be increased in response to hypoxia in gastric cancer cell lines (Liang et al., 2007b). Other PrPC-inducing signals include oxidative (Sauer et al., 1999) and endoplasmic-reticulum (Dery et al., 2013) stresses. Some deregulation of PrPC function may also arise with aging. Indeed, PrPC was recently shown to accumulate in lipid rafts in the mouse aging brain (Agostini et al., 2013). Whether this change in PrPC distribution also occurs in other tissues with aging is worth considering, since it would potentially impact on the recruitment of downstream signaling cascades. As observed in the context of neurodegeneration (Hirsch et al., 2014), the subversion of PrPC function may over-activate src kinases and further promote alterations in lipid raft-initiated signaling pathways, known to be detrimental in cancer (Patra, 2008). Such changes may in turn have consequences on the cell local environment, and, in the case of stem cells, deregulate the interactions with their niche. This scenario is considered as a potential cause of CSCs emergence (Rezza et al., 2014), and this may have particular relevance with respect to aging.

Open questions and therapeutic prospects

Harnessing the self-renewal and differentiation potential of stem cells represents a major challenge for regenerative medicine. The recent accumulation of data regarding the involvement of PrPC in stem cell biology warrants further studying the molecular and cellular mechanisms sustaining the contribution of this protein to the proliferation of stem cells, their maintenance in an undifferentiated state, their capacity to respond to fate determination inputs and to implement a given differentiation program. Achieving this task is complicated by the multiplicity of PrPC isoforms and partners, which may fulfill promiscuous functions. That PrPC is required for efficient tissue repair after injury is clearly indicated in the context of bone-marrow reconstitution (Zhang et al., 2006) or muscle regeneration (Stella et al., 2010), which suggest that the mobilization of PrPC-dependent cascades via appropriate ligands may provide a fruitful approach to enhance the regeneration of lesionned tissues. As a prerequisite, manipulating conditions would need to be carefully adjusted in order to control activating signals, given the pathological implications that may ensue from PrPC over-activation. Finally, the emerging roles of PrPC in stemness on the one hand and in various aspects of cancer cell biology on the other hand bring new light on this already fascinating molecule. Given the relationship between stem cells and oncogenesis, advance in the understanding of the role played by PrPC in stem cells is likely to illuminate the issue of its contribution to tumorigenesis and vice-versa. One major remaining challenge is to decipher the mechanisms controlling the expression levels of PrPC in normal and cancer stem cells. While the cues underlying the induction of PrPC during embryonic development are elusive, several cancer-associated conditions, including hypoxia (Liang et al., 2007b), oxidative (Sauer et al., 1999) or endoplasmic reticulum (Dery et al., 2013) stresses have been reported to activate PrPC transcription. More broadly, increasing our knowledge of the regulation of PrP gene expression may help design novel strategies for therapeutic intervention in cancer, beyond directly targeting PrPC through antisense oligonucleotides (Meslin et al., 2007) or monoclonal antibodies (Du et al., 2013). To conclude, progress in the stem cell and cancer fields should increase our knowledge of how PrPC, as a cell surface receptor or co-receptor, connects cells with their environment to drive adaptive, homeostatic responses and how this function is corrupted in disease-associated states.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  69 in total

1.  Cellular prion protein promotes regeneration of adult muscle tissue.

Authors:  Roberto Stella; Maria Lina Massimino; Marco Sandri; M Catia Sorgato; Alessandro Bertoli
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

2.  The expression of prion protein (PrP(C)) in the megakaryocyte lineage.

Authors:  R Starke; P Harrison; I Mackie; G Wang; J D Erusalimsky; R Gale; J-M Massé; E Cramer; A Pizzey; J Biggerstaff; S Machin
Journal:  J Thromb Haemost       Date:  2005-06       Impact factor: 5.824

3.  Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro.

Authors:  Jamil Kanaani; Stanley B Prusiner; Julia Diacovo; Steinunn Baekkeskov; Giuseppe Legname
Journal:  J Neurochem       Date:  2005-12       Impact factor: 5.372

4.  Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS.

Authors:  Jie Liang; Yanglin Pan; Dexin Zhang; Changcun Guo; Yongquan Shi; Jingbo Wang; Yu Chen; Xin Wang; Jie Liu; Xuegang Guo; Zheng Chen; Taidong Qiao; Daiming Fan
Journal:  FASEB J       Date:  2007-04-04       Impact factor: 5.191

Review 5.  Adult stem cell niches: cellular and molecular components.

Authors:  Amélie Rezza; Rachel Sennett; Michael Rendl
Journal:  Curr Top Dev Biol       Date:  2014       Impact factor: 4.897

6.  Neural stem cell model for prion propagation.

Authors:  Ollivier Milhavet; Danielle Casanova; Nathalie Chevallier; Ronald D G McKay; Sylvain Lehmann
Journal:  Stem Cells       Date:  2006-06-01       Impact factor: 6.277

7.  Mice devoid of PrP are resistant to scrapie.

Authors:  H Büeler; A Aguzzi; A Sailer; R A Greiner; P Autenried; M Aguet; C Weissmann
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

8.  CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Yuanyuan Cheng; Lili Tao; Jiawen Xu; Qingquan Li; Juan Yu; Yiting Jin; Qi Chen; Zude Xu; Qiang Zou; Xiuping Liu
Journal:  Mol Carcinog       Date:  2013-05-16       Impact factor: 4.784

Review 9.  Adult neural stem cells: an endogenous tool to repair brain injury?

Authors:  Gian Carlo Bellenchi; Floriana Volpicelli; Valerio Piscopo; Carla Perrone-Capano; Umberto di Porzio
Journal:  J Neurochem       Date:  2012-12-05       Impact factor: 5.372

10.  A new paradigm for enzymatic control of α-cleavage and β-cleavage of the prion protein.

Authors:  Alex J McDonald; Jessie P Dibble; Eric G B Evans; Glenn L Millhauser
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

View more
  26 in total

Review 1.  The double life of the ribosome: When its protein folding activity supports prion propagation.

Authors:  Cécile Voisset; Marc Blondel; Gary W Jones; Gaëlle Friocourt; Guillaume Stahl; Stéphane Chédin; Vincent Béringue; Reynald Gillet
Journal:  Prion       Date:  2017-03-04       Impact factor: 3.931

Review 2.  Targeting prion protein interactions in cancer.

Authors:  Tiago G Santos; Marilene H Lopes; Vilma R Martins
Journal:  Prion       Date:  2015       Impact factor: 3.931

3.  Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicin-induced apoptosis.

Authors:  Cornelius Kwang-Lee Chieng; Yee-How Say
Journal:  Tumour Biol       Date:  2015-05-17

4.  Promiscuous functions of the prion protein family.

Authors:  Sophie Mouillet-Richard; Jean-Luc Vilotte
Journal:  Front Cell Dev Biol       Date:  2015-02-10

5.  Prion Protein Modulates Monoaminergic Systems and Depressive-like Behavior in Mice.

Authors:  Danielle Beckman; Luis E Santos; Tatiana A Americo; Jose H Ledo; Fernando G de Mello; Rafael Linden
Journal:  J Biol Chem       Date:  2015-07-07       Impact factor: 5.157

6.  Role of Prion protein-EGFR multimolecular complex during neuronal differentiation of human dental pulp-derived stem cells.

Authors:  Stefano Martellucci; Valeria Manganelli; Costantino Santacroce; Francesca Santilli; Luca Piccoli; Maurizio Sorice; Vincenzo Mattei
Journal:  Prion       Date:  2018-05-04       Impact factor: 3.931

7.  Tumor resistance to radiotherapy is triggered by an ATM/TAK1-dependent-increased expression of the cellular prion protein.

Authors:  Jacqueline Bernardino-Sgherri; Capucine Siberchicot; Frédéric Auvré; Didier Busso; Clémentine Brocas; Ghazi El Masri; Anna Lioutsko; Federica Ferri; J Pablo Radicella; Paul-Henri Romeo; Anne Bravard
Journal:  Oncogene       Date:  2021-03-25       Impact factor: 9.867

8.  Common themes in PrP signaling: the Src remains the same.

Authors:  Katharina Ochs; Edward Málaga-Trillo
Journal:  Front Cell Dev Biol       Date:  2014-10-28

Review 9.  Prion protein (PrP) gene-knockout cell lines: insight into functions of the PrP.

Authors:  Akikazu Sakudo; Takashi Onodera
Journal:  Front Cell Dev Biol       Date:  2015-01-15

Review 10.  The Cellular Prion Protein: A Player in Immunological Quiescence.

Authors:  Maren K Bakkebø; Sophie Mouillet-Richard; Arild Espenes; Wilfred Goldmann; Jörg Tatzelt; Michael A Tranulis
Journal:  Front Immunol       Date:  2015-09-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.